


# Accepted Manuscript

The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults

Patrick Darken, Paolo DePetrillo, Colin Reisner, Earl St Rose, Paul Dorinsky



PII: S1094-5539(17)30254-7

DOI: [10.1016/j.pupt.2018.03.001](https://doi.org/10.1016/j.pupt.2018.03.001)

Reference: YPUPT 1713

To appear in: *Pulmonary Pharmacology & Therapeutics*

Received Date: 23 October 2017

Revised Date: 26 February 2018

Accepted Date: 12 March 2018

Please cite this article as: Darken P, DePetrillo P, Reisner C, Rose ES, Dorinsky P, The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults, *Pulmonary Pharmacology & Therapeutics* (2018), doi: 10.1016/j.pupt.2018.03.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**The pharmacokinetics of three doses of  
budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose  
inhaler compared with active controls: A Phase I randomized, single-dose,  
crossover study in healthy adults**

Patrick Darken<sup>a\*</sup>, Paolo DePetrillo<sup>b</sup>, Colin Reisner<sup>c</sup>, Earl St Rose<sup>a</sup>, Paul Dorinsky<sup>d</sup>

<sup>a</sup>*Pearl – A member of the AstraZeneca Group, Morristown, NJ, USA*

<sup>b</sup>*Pharmaron, Baltimore, MD, USA*

<sup>c</sup>*Pearl – A member of the AstraZeneca Group, Morristown NJ, USA and AstraZeneca, Gaithersburg, MD, USA*

<sup>d</sup>*Pearl – A member of the AstraZeneca Group, Durham, NC, USA*

**\*Corresponding Author:** Pearl – A member of the AstraZeneca Group, 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960, USA

*E-mail address:* pdarken@pearltherapeutics.com (P Darken)

*Phone number:* +1 973 975 0338

Dr Paolo DePetrillo, Pharmaron, 800 W. Baltimore St., Baltimore, MD 21201, USA. Email:

paolo.depetrillo@pharmaron-us.com

Dr Colin Reisner, Pearl – A member of the AstraZeneca Group, 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960, USA. Email: creisner@pearltherapeutics.com

Dr Earl St Rose, Pearl – A member of the AstraZeneca Group, 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960, USA. Email: estrose@pearltherapeutics.com

Dr Paul Dorinsky, Pearl – A member of the AstraZeneca Group, 4222 Emperor Boulevard, Suite 560, Durham, NC 27703, USA. Email: pdorinsky@pearltherapeutics.com

Download English Version:

<https://daneshyari.com/en/article/8537711>

Download Persian Version:

<https://daneshyari.com/article/8537711>

[Daneshyari.com](https://daneshyari.com)